Practical advice on clinical decision making during neoadjuvant chemotherapy for primary breast cancer

Surgical Oncology

Volumn 18, Issue 1, 2009, Pages 65-71

  Shenoy, H G ^a   Peter, M B ^a   Masannat, Y A ^a   Dall, B J G ^a   Dodwell, D ^b   Horgan, K ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Locally advanced disease; Neoadjuvant chemotherapy; Operable breast cancer

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; MITOXANTRONE; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ASPIRATION BIOPSY; ASSAULT; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; FOLLOW UP; HUMAN; PATIENT DECISION MAKING; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TUMOR BIOPSY;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DECISION MAKING; FEMALE; HUMANS; NEOADJUVANT THERAPY;

EID: 60249088383     PISSN: 09607404     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suronc.2008.07.005     Document Type: Review

References (49)

1. De Lena M., Zucati R., Viganotti G., Valagussa P., and Bonnadonna G. Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol 1 1 (1978) 53-59
2. Mieog J.S.D., Van der Hage J.A., and Van de Velde C.J.H. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg 94 10 (2007) 1189-1200
3. Bear H.D., Anderson S., Smith R.E., Geyer C.E.J., Mamounas E.P., Fisher B., et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24 13 (2006) 2019-2027
4. Von Minckwitz G., Blohmer J.U., Raab G., Lohr A., Gerber B., Heinrich G., et al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 16 1 (2005) 56-63
5. Dawood S., Broglio K., Kau S.W., Islam R., Symmans W.F., Buchholz T.A., et al. Prognostic value of initial clinical disease stage after achieving pathological complete response. Oncologist 13 1 (2008) 6-15
6. Cleator S.J., Makris A., Ashley S.E., Lal R., and Powles T.J. Good clinical response of breast cancers to neoadjuvant chemo-endocrine therapy is associated with improved overall survival. Ann Oncol 16 (2005) 267-272
7. Ellis P., Smith I., Ashley S., Walsh G., Ebbs S., Baum M., et al. Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J Clin Oncol 16 1 (1998) 107-114
8. Klauber-DeMore N., Ollila D.W., Moore D.T., Livasy C., Calvo B.F., Kim H.J., et al. Size of residual lymph node metastasis after neoadjuvant chemotherapy in locally advanced breast cancer patients is prognostic. Ann Surg Oncol 13 5 (2006 May 1) 685-691
9. Rajan R., Esteva F.J., and Symmans W.F. Pathologic changes in breast cancer following neoadjuvant chemotherapy: implications for the assessment of response. Clin Breast Cancer 5 3 (2004) 235-238
10. Piper G.L., Patel N.A., Patel J.A., Malay M.B., and Julian T.B. Neoadjuvant chemotherapy for locally advanced breast cancer results in alterations in preoperative tumour marker status. Am Surg 70 12 (2004) 1103-1106
11. Kaufmann M., Von Minckwitz G., Bear H.D., Buzdar A., McGale P., Bonnefoi H., et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 18 12 (2007) 1927-1934
12. Wolmark N., Wang J., Mamounas E., Bryant J., and Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. JNCI Monographs 2001 30 (2001) 96-102
13. Mauri D., Pavlidis N., and Ioannidis J.P.A. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 97 3 (2005) 188-194
14. Rustogi A., Budrukkar A., Dinshaw K., and Jalali R. Management of locally advanced breast cancer: evolution and current practice. J Cancer Res Ther 1 1 (2005) 21-30
15. Goldhirsch A., Wood W.C., Gelber R.D., Coates A.S., Thürlimann B., and Senn H.J. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18 7 (2007) 1133-1144
16. Gianni L., Zambetti M., Clark K., Baker J., Cronin M., Wu J., et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23 29 (2005) 7265-7277
17. Ring A.E., Smith I.E., Ashley S., Fulford L.G., and Lakhani S.R. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer 91 12 (2004) 2012-2017
18. Amat S., Bougnoux P., Penault-Llorca F., Fétissof F., Curé H., Kwiatkowski F., et al. Neoadjuvant docetaxel for operable breast cancer induces a high pathologic response and breast-conservation rate. Br J Cancer 88 (2003) 1339-1345
19. Wenzel C., Hussian D., Bartsch R., Pluschnig U., Locker G.J., Rudas M., et al. Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study. J Cancer Res Clin Oncol 130 7 (2004) 400-404
20. Hurley J., Dolini P., Silva O., Gomez-Fernandez C., Reis I., Velez P., et al. Neoadjuvant herceptin/taxotere/cisplatin in the treatment of locally advanced and inflammatory breast cancer. Proc Am Soc Clin Oncol 21 (2002) abstract 196
21. Baselga J., Semiglazov V., Manikhas G.M., Eiermann W., Lluch A., Tjulandin S., et al. Efficacy of neoadjuvant trastuzumab in patients with inflammatory breast cancer: data from the NOAH (NeOAdjuvant Herceptin) Phase III trial. Eur J Cancer Suppl 5 4 (2007) 193
22. Gianni V., Semiglazov G.M., Manikhas W., Eiermann A., Lluch S., Tjulandin A., et al. Neoadjuvant trastuzumab in locally advanced breast cancer (NOAH): antitumour and safety analysis. J Clin Oncol 18S (2007) 25 abstract 532
23. Buzdar A.U., Ibrahim N.K., Francis D., Booser D.J., Thomas E.S., Theriault R.L., et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23 16 (2005) 3676-3685
24. Warren R. Is breast MRI mature enough to be recommended for general use?. Lancet 358 9295 (2001) 1745-1746
25. Nason K.S., Anderson B.O., Byrd D.R., Dunnwald L.K., Eary J.F., Mankoff D.A., et al. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer 89 11 (2000) 2187-2194
26. Newman E.A., Sabel M.S., Nees A.V., Schott A., Diehl K.M., Cimmino V.M., et al. Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation. Ann Surg Oncol 14 10 (2007) 2946-2952
27. Haid A., Tausch C., Lang A., Lutz J., Fritzsche H., Peschina W., et al. Is sentinel lymph node biopsy reliable and indicated after preoperative chemotherapy in patients with breast carcinoma?. Cancer 92 5 (2001) 1080-1084
28. Xing Y., Foy M., Cox D.D., Kuerer H.M., Hunt K.K., and Cormier J.N. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg 93 (2006) 539-546
29. Mamounas E.P. Sentinel lymph node biopsy after neoadjuvant systemic therapy. Surg Clin North Am 83 4 (2003) 931-942
30. Jones J.L., Zabicki K., Christian R.L., Gadd M.A., Hughes K.S., Lesnikoski B.A., et al. A comparison of sentinel node biopsy before and after neoadjuvant chemotherapy: timing is important. Am J Surg 190 4 (2005) 517-520
31. Van Rijk M.C., Nieweg O.E., Rutgers E.J., Oldenburg H.S., Olmos R.V., Hoefnagel C.A., et al. Sentinel node biopsy before neoadjuvant chemotherapy spares breast cancer patients axillary lymph node dissection. Ann Surg Oncol 13 4 (2006) 475-479
32. Sabel M.S., Schott A.F., Kleer C.G., Merajver S., Cimmino V.M., Diehl K.M., et al. Sentinel node biopsy prior to neoadjuvant chemotherapy. Am J Surg 186 2 (2003) 102-105
33. Cox C., Furman B., Stowell N., White L., Clark J., Dupont E., et al. Sentinel node biopsy prior to neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer. Ann Surg Oncol 11 S2 (2004) S99
34. Cox C.E., Cox J.M., White L.B., Stowell N.G., Clark J.D., Allred N., et al. Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer. Ann Surg Oncol 13 4 (2006) 483-490
35. Rosen E.L., Blackwell K.L., Baker J.A., Soo M.S., Bentley R.C., Yu D., et al. Accuracy of MRI in the selection of residual breast cancer after chemotherapy. AJR Am J Roentgenol 181 5 (2003) 1275-1282
36. Rieber A., Brambs H.J., Gabelmann A., Heilmann V., Kreienberg R., and Kühn T. Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy. Eur Radiol 12 7 (2002) 1711-1719
37. Warren R.M., Bobrow L.G., Earl H.M., Britton P.D., Gopalan D., Purushotham A.D., et al. Can breast MRI help in the management of women with breast cancer treated by neoadjuvant chemotherapy?. Br J Cancer 90 (2004) 1349-1360
38. Schott A.F., Roubidoux M.A., Helvie M.A., Hayes D.F., Kleer C.G., Newman L.A., et al. Clinical and radiological assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat 92 3 (2005) 231-238
39. Rieber A., Zeitler H., Rosenthal H., Görich J., Kreienberg R., Brambs H.J., et al. MRI of breast cancer: influence of chemotherapy on sensitivity. Br J Radiol 70 833 (1997) 452-458
40. Martincich L., Montemurro F., De Rosa G., Marra V., Ponzone R., Cirillo S., et al. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res Treat 83 1 (2004) 67-76
41. Edeiken B.S., Fornage B., Bedi D.G., Singletary S.E., Ibrahim N.K., Strom E.A., et al. US-guided implantation of metallic markers for permanent localization of the tumour bed in patients with breast cancer who undergo preoperative chemotherapy. Radiology 213 3 (1999) 895-900
42. Julius T., Kemp S.E., Kneeshaw P.J., Chaturvedi A., Drew P.J., and Turnbull L.W. MRI and conservative treatment of locally advanced breast cancer. Eur J Surg Oncol 31 10 (2005) 1129-1134
43. Chagpar A.B., Middleton L.P., Sahin A.A., Dempsey P., Buzdar A., Mirza A.N., et al. Accuracy of physical examination, ultrasonography and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg 243 2 (2006) 257-264
44. Green M.C., and Hortobagyi G.N. Chemotherapy for breast cancer (2001), Springer, New York
45. Le Bouëdec G., Charrier S., Curé H., Peffault de Latour M., Ferrière J.P., Chollet P., et al. Neoadjuvant chemotherapy of breast cancer. Role of surgery in cases of complete clinical response. Presse Med 28 39 (1999) 2145-2148
46. Pendas S., Jakub J., Giuliano R., Gardner M., Swor G.B., and Reintgen D.S. The role of sentinel lymph node biopsy in patients with ductal carcinoma in situ or with locally advanced breast cancer receiving neoadjuvant chemotherapy. Cancer Control 11 4 (2004) 231-235
47. Abrial S.C., Penault-Llorca F., Delva R., Bougnoux P., Leduc B., Mouret-Reynier M.A., et al. High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat 94 (2005) 255-263
48. Kuerer H.M., Sahin A.A., Hunt K.K., Newman L.A., Breslin T.M., Ames F.C., et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg 230 1 (1999) 72-78
49. Hennessy B.T., Hortobagyi G.N., Rouzier R., Kuerer H., Sneige N., Buzdar A.U., et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 23 36 (2005) 9304-9311